Urogen Pharma Stock News

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th

Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive

Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []

Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []

UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Jason Drew Smith sold 3,803 shares of the firms stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total transaction of $45,750.09. The transaction was disclosed in a filing with the SEC, which is accessible through this link. []

Wall Street brokerages predict that UroGen Pharma Ltd. (NASDAQ:URGN) will post earnings of ($1.27) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from ($1.39) to ($1.08). UroGen Pharma reported earnings of ($1.38) per share during the same quarter last year, which []

UroGen Pharma Ltd. (NASDAQ:URGN) CFO Molly Henderson sold 2,587 shares of the companys stock in a transaction that occurred on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total value of $31,121.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Nuveen Asset Management LLC decreased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 5.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 96,600 shares of the companys stock after selling 6,054 shares during the period. Nuveen Asset Management LLC owned approximately 0.46% of UroGen Pharma []

Wall Street analysts expect that UroGen Pharma Ltd. (NASDAQ:URGN) will announce $17.20 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from $16.50 million to $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last year, which would [] The post Zacks: Analysts Anticipate UroGen Pharma Ltd. (NASDAQ:URGN) Will Announce Quarterly Sales of $17.20 Million appeared first on ETF Daily News .